Disc Medicine IRON Other Segment Items — Segment Reporting Other Item Amount
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Disc Medicine in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Disc Medicine's other segment items — segment reporting other item amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Disc Medicine's other segment items — segment reporting other item amount?
- Disc Medicine (IRON) reported other segment items — segment reporting other item amount of $6.02M in Q1 2026.
- How has Disc Medicine's other segment items — segment reporting other item amount changed year-over-year?
- Disc Medicine's other segment items — segment reporting other item amount increased by 2.7% year-over-year, from $5.86M to $6.02M.
- What is the long-term trend for Disc Medicine's other segment items — segment reporting other item amount?
- Over 2 years (2023 to 2025), Disc Medicine's other segment items — segment reporting other item amount has grown at a 27.4% compound annual growth rate (CAGR), from $14.7M to $23.84M.
- What does other segment items — segment reporting other item amount mean?
- This metric represents the aggregate financial impact of miscellaneous activities, corporate overhead, or non-core operational expenses that are not allocated to the company's primary therapeutic development segments. It captures costs or income streams that fall outside the scope of specific clinical programs, providing insight into the scale of administrative or unallocated corporate functions. Monitoring this figure helps investors understand the baseline operational burden required to support the company's broader biopharmaceutical research and development infrastructure.